Recombinant Escherichia RELB Protein，His

RELB, a member of the NF-κB family of transcription factors, plays a crucial role in immune response, inflammation, and cell survival. Research on RELB has gained momentum due to its involvement in various pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders. Unlike its better-studied counterparts, such as NF-κB p65, RELB operates primarily in the context of the non-canonical NF-κB signaling pathway, which is triggered by specific receptors, including BAFFR and CD40. This pathway is essential for the development of certain immune cells, particularly dendritic cells and B cells. Dysregulation of RELB activity is implicated in tumor progression and the modulation of immune responses, making it a potential therapeutic target. Studies have shown that RELB can promote cell survival and proliferation, highlighting its dual role in both enhancing immune responses and facilitating tumor growth. Investigating the mechanisms by which RELB influences various cellular processes is critical for understanding its contributions to health and disease. Furthermore, as RELB functions in a network with other signaling molecules, elucidating its interactions and regulatory mechanisms could provide insights into novel therapeutic strategies aimed at modulating immune responses and treating related diseases. Consequently, the study of RELB is not only significant for basic biological research but also holds promise for clinical advancements in targeted therapies against cancer and inflammatory diseases.